Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database
J Qian, S Zhang, C Jiang - BMC cancer, 2024 - Springer
Selpercatinib, a highly selective tyrosine kinase inhibitor, has emerged as an excellent
treatment option for patients with rearranged during transfection-altered cancer. However …
treatment option for patients with rearranged during transfection-altered cancer. However …
[HTML][HTML] Selpercatinib and pralsetinib induced chylous ascites in RET-rearranged lung adenocarcinoma: a case series
J Fricke, J Wang, N Gallego, I Mambetsariev, P Kim… - Clinical Lung Cancer, 2023 - Elsevier
Clinical Practice Points• The selective RET-TKIs, ie, selpercatinib and pralsetinib are
effective against RET fusions in patients with NSCLC.• Chylous ascites (CA) is an extremely …
effective against RET fusions in patients with NSCLC.• Chylous ascites (CA) is an extremely …